Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daytrana Approval For Adolescents Gives Shire's ADHD Drug A New Lease On Life

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the patch were down 10 percent last year due to recalls caused by manufacturing problems.

You may also be interested in...

Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion

FDA says that Intuniv patient materials claimed it treats such non-ADHD behavioral problems as temper outbursts.

Did Vyvanse Internet Ads Draw A Subpoena? Shire ADHD Promotions Get Government's Attention

HHS' request for documents comes as Shire launches new marketing campaigns and co-promotion with GlaxoSmithKline.

FDA’s Advertising Enforcement Turns Its Focus To YouTube, ADHD Drugs

FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts